Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter and full year ended December 31, 2025.

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today outlined 2026 as a program-defining year for allogeneic CAR T, with multiple first-half clinical readouts expected to test, and potentially validate, whether off-the-shelf CAR T can be delivered at biologic-like scale, in real-world settings, across oncology and autoimmune disease.

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today noted the favorable outcome for Servier in its arbitration with Cellectis (Euronext Growth: ALCLS –  NASDAQ: CLLS) as it relates to cemacabtagene ansegedleucel (cema-cel).

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology Treatment Additional Sites in Australia and South Korea Expected to Open in early 2026 Scheduled Futility Analysis, Focused on MRD Conversion Between Study Arms, on Track for 1H 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) ALLO-329, a Dual CD19/CD70 CAR, Harnesses the Dagger® Technology to Reduce or Eliminate Lymphodepletion RESOLUTION Basket Trial in Rheumatology Enrolling with Proof-of-Concept Data Planned for 1H 2026 Phase 1 TRAVERSE Trial with ALLO-316 in Renal Cell Carcinoma (RCC) ALLO-316 Achieves Durable Responses in RCC Representing a Potential Breakthrough for CAR T in Solid Tumors; Plans Ongoing to Determine the Next Phase of the Program Ended Q3 2025 with $277.1 Million in Cash, Cash Equivalents and Investments; Cash Runway Continued to be Projected Into 2H 2027 Conference Call and Webcast Scheduled for Today at 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended September 30, 2025.